SENP6 anticorps (C-Term)
Aperçu rapide pour SENP6 anticorps (C-Term) (ABIN2784245)
Antigène
Voir toutes SENP6 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Séquence
- MNLANWFPPP RMRTKREEIR NIILKLQEDQ SKEKRKHKDT YSTEAPLGEG
-
Homologie
- Cow: 79%, Horse: 79%, Human: 100%, Pig: 91%
-
Attributs du produit
- This is a rabbit polyclonal antibody against SENP6. It was validated on Western Blot using a cell lysate as a positive control.
-
Purification
- Affinity Purified
-
Immunogène
- The immunogen is a synthetic peptide directed towards the C terminal region of human SENP6
-
-
-
-
Indications d'application
- Optimal working dilutions should be determined experimentally by the investigator.
-
Commentaires
-
Antigen size: 1105 AA
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
- SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))
-
Autre désignation
- SENP6
-
Sujet
-
SENP6 is a UBL-specific protease that deconjugates SUMO1, SUMO2 and SUMO3 from targeted proteins. It does not seem to be involved in the processing of full-length SUMO proteins to their mature forms. SENP6 deconjugates SUMO1 from RXRA, leading to transcriptional activation. It may act preferentially on substrates containing 3 or more SUMO2 or SUMO3 moieties.Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1, MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA, MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM].
Alias Symbols: FLJ11355, FLJ11887, KIAA0389, KIAA0797, SSP1, SUSP1
Protein Interaction Partner: UBC, SP1, LMNA, COPS5, SUMO2, KAT5, SUMO1, PLA2G2A, RUVBL2, ARNT,
Protein Size: 1105 -
Poids moléculaire
- 125 kDa
-
ID gène
- 26054
-
NCBI Accession
- NM_001100409, NP_001093879
-
UniProt
- Q9GZR1
Antigène
-